指南与共识放疗物理与技术姑息放疗与转移瘤

荷兰放疗患者心脏植入电子设备管理指南更新

Updated Dutch guideline for management of radiation oncology patients with a pacemaker, implantable cardioverter defibrillator or non-cardiac active implant.
指南 / 共识 · Radiother Oncol · 2026-04-10

该指南基于文献综述与全国调查更新2011版荷兰指南,纳入MR-linac、质子治疗及非心脏有源植入物。文献发现设备故障主要见于中子产额高的束流(>10 MV光子或质子),全国4942例CIED患者中仅报告少量事件。更新推荐按中子暴露分层,简化光子/电子束监测流程。

要点

  • 心动过速治疗在放疗期间无需停用。
  • 光子≤10 MV或电子束且CIED累积剂量<10 Gy时无需额外检查。
  • 设备故障主要见于>10 MV光子或质子等中子产额高的束流。

核心结论

  • 更新指南采用基于中子暴露而非单纯光子/电子剂量的风险分层方法,简化了绝大多数光子/电子束放疗患者的监测流程。

研究设计与样本

  • 多学科工作组制定,基于Embase和Ovid/Medline检索2008年以来文献,并对所有荷兰放疗中心进行问卷调查。

主要发现

  • 文献检索识别374篇独特出版物并筛选分析。
  • 设备故障主要发生于中子产额高的束流(>10 MV光子或质子)。
  • 调查应答率100%,2011至2022年荷兰4942例CIED放疗患者中报告5例重置、2例电池寿命缩短和3例短暂设备故障。

关键数值与推荐

  • 推荐心动过速治疗在放疗期间无需停用。
  • 光子能量≤10 MV或使用电子束且CIED累积剂量<10 Gy时,无需额外CIED检查。
  • 为MR-linac治疗和非心脏有源植入物提供推荐。

临床怎么用

  • 对使用光子≤10 MV或电子束且CIED累积剂量<10 Gy的患者,可简化监测流程。
  • 对使用>10 MV光子或质子等中子产额高束流的患者,需按风险分层加强管理。
  • 放疗期间无需停用心动过速治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To revise and expand the 2011 Dutch guideline for radiotherapy in patients with cardiac implantable electronic devices (CIEDs), incorporating MR-linac treatment, proton therapy, and non-cardiac active implants. METHODS AND MATERIALS: A literature review was performed using Embase and Ovid/Medline, covering studies from 2008 onwards. In addition, a survey was conducted among all Dutch radiation oncology centres to assess CIED-related incidents and current clinical practices. The updated guideline was developed by a multidisciplinary task group. RESULTS: The literature search identified 374 unique publications which were screened for relevance and analysed. Device malfunctions were found to occur predominantly with neutron-producing beam energies (> 10 MV photons or protons). The survey achieved a 100% response rate and reported only five resets, two cases of reduced battery longevity, and three transient devise malfunctions among 4942 radiotherapy patients with CIEDs treated in the Netherlands between 2011 and 2022. Based on these findings and literature, the updated guideline recommends that tachycardia therapies do not need to be deactivated during radiotherapy and that additional CIED checks are not required when photon energies ≤ 10 MV or electron beams are used and the cumulative CIED dose is < 10 Gy. Furthermore, recommendations for MR-linac treatment and non-cardiac implants are provided. CONCLUSIONS: The updated Dutch guideline introduces a risk-stratified approach based on neutron exposure rather than photon/electron dose alone. It simplifies monitoring protocols for nearly all radiotherapy patients treated with photons and electrons and extends guidance to newer treatment modalities and device types, thereby ensuring patient safety while streamlining radiotherapy workflows.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Jansen WPA, Koken PW, de Jong RA, et al. Updated Dutch guideline for management of radiation oncology patients with a pacemaker, implantable cardioverter defibrillator or non-cardiac active implant. Radiother Oncol. 2026. PMID: 41967607. doi:10.1016/j.radonc.2026.111529

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。